Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832851 | 1.00 | UCHL1 (0.50) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL20571049 | 0.92 | UCHL1 (0.46) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL30955266 | 0.89 | NOTUM (0.50) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL27438071 | 0.89 | NOTUM (0.50) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL30955281 | 0.87 | HDAC1 (0.53) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL2022337 | 0.87 | HDAC1 (0.53) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL23063791 | 0.83 | NOTUM (0.64) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL3902861 | 0.83 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL31014046 | 0.83 | UCHL1 (0.52) | UCHL1NOTUMKDM1AHDAC1HDAC6 | |
| SCHEMBL29535019 | 0.83 | UCHL1 (0.67) | UCHL1NOTUMKDM1AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220213093-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114072405-A | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| WO-2021001330-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-01-07 | — | — | WO | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213093-A1 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, PNLIP, LIPC | UCHL1 172/4885NOTUM 62/4885KDM1A 1040/4885 |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | UCHL1 294/4885NOTUM 4088/4885KDM1A 2140/4885 |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | UCHL1 370/4885NOTUM 3896/4885KDM1A 2377/4885 |
| US-12637454-B2 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | MGLL, LIPA, LIPC | UCHL1 134/4885NOTUM 65/4885KDM1A 1259/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | UCHL1 294/4885NOTUM 4088/4885KDM1A 2140/4885 |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | UCHL1 294/4885NOTUM 4088/4885KDM1A 2140/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | UCHL1 370/4885NOTUM 3896/4885KDM1A 2377/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | UCHL1 294/4885NOTUM 4088/4885KDM1A 2140/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | UCHL1 370/4885NOTUM 3896/4885KDM1A 2377/4885 |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | UCHL1 294/4885NOTUM 4088/4885KDM1A 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.